Las bodas de diamante de la clorpromazina

  1. Medrano Albéniz, Juan
Zeitschrift:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Datum der Publikation: 2012

Ausgabe: 32

Nummer: 116

Seiten: 851-866

Art: Artikel

DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Revista de la Asociación Española de Neuropsiquiatría

Bibliographische Referenzen

  • (1) Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007 August; 3(4): 495–500 [Accesible en: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2655089/pdf/NDT-3-495. pdf].
  • (2) Mazana JS, Pereira J, Cabrera R. Cincuenta años de clorpromazina. Rev Esp Sanid Penit 2002; 4: 101-113 [Accesible en: http://www.sanipe.es/OJS/index.php/RESP/ article/view/234/517].
  • (3) Mitchell P. Chlorpromazine turns forty. Aust N Z J Psychiatry 1993; 27: 370-3 [Accesible en: http://anp.sagepub.com/content/27/3/370.full.pdf].
  • (4) De Bedia A. De la efectividad et la especificidad de las orasciones a los santos Cosme et Damián cuando de sanar los males de los hommes enfermos tratan nuestras labors. Txor Herr Med J 1992; 2(1) [Accesibnle en: http://www.txoriherri.org/especificidad.htm].
  • (5) Food and Drug Administration. Methylene Blue: Drug Safety Communication Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications, 10/21/2011 [Acc en: http:// www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265476.htm].
  • (6) Bender KJ. Methylene blue studied for bipolar as FDA issues warning. Psychiatric Times 10/5/2011 [Accesible en: http:// www.psychiatrictimes.com/bipolar-disorder/ content/article/10168/1963962].
  • (7) Hamon J, Paraire J, Velluz J.Remarques sur l’action du 4560 RP sur l’agitation maniaque. Ann Méd Psychol (Paris) 1952; 110:331–5.
  • (8) King C, Voruganti LNP. What’s in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci 2002; 27: 168-75 [Accesible en: http://www. cma.ca/multimedia/staticContent/HTML/ N0/l2/jpn/vol-27/issue-3/pdf/pg168.pdf].
  • (9) Healy D. The creation of psychopharmacology. Cambridge, Massachussets: Harvard University Press, 2002
  • (10) Lehmann HE. Before they called it Psychopharmacology. Neuropsychopharmacology 1993; 8: 291-303
  • (11) Etain B, Roubaud L. Jean Delay, M.D., 1907–1987. Am J Psychiatry 2002;159:1489 [Accesible en: http://ajp.psychiatryonline.org/article. aspx?articleid=175748].
  • (12) Creese I, Burt R, Snyder SH. Dopamine receptor binding; differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Science 1975; 17: 993–1001.
  • (13) Burt DR, Enna SJ, Creese I, Snyder SH. Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci U S A 1975; 72: 4655-9 [Accesible en: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC388782/pdf/pnas00062- 0469.pdf].
  • (14) Creese I, Burt R, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/3854].
  • (15) Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fish- man R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198: 51-8 [Accesible en: http://bjp.rcpsych. org/content/198/1/51.long].
  • (16) Bobon J, Bobon DP, Pinchard A, Collard J, Ban TA, De Buck R, Hippius H, et al. A new comparative physiognomy of neuroleptics: a collaborative clinical report. Acta Psychiatr Belg 1972; 72: 542-54.
  • (17) Leucht S, Pitschel-Walz G, Engel RR, Kissling W..Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180-90 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/11823257].
  • (18) Glazer WM. Does loxapine have “atypical” properties? Clinical evidence. J Clin Psychiatry 1999; 60 Suppl 10: 42-6 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/10340686].
  • (19) Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, et al. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology 2005; 30: 2236-44 [Accesible en: http://www.nature.com/npp/journal/v30/n12/full/1300796a. html].
  • (20) Dall’Igna OP, Tort AB, Souza DO, Lara DR. Cinnarizine has an atypical antipsychotic profile in animal models of psychosis J Psychopharmacol 2005; 19: 342- 6 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/15982988].
  • (21) Tort AB, Dall’Igna OP, de Oliveira RV, Mantese CE, Fett P, Gomes MW, et al. Atypical antipsychotic profile of flunarizine in animal models. Psychopharmacology (Berl) 2005; 177: 344-8 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/15290004].
  • (22) Bisol LW, Brunstein MG, Ottoni GL, Ramos FL, Borba DL, Daltio CS, et al. Is flunarizine a long-acting oral atypical an- tipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J Clin Psychiatry 2008; 69: 1572-9 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/19192440].
  • (23) Jindal RD, Keshavan MS. Classifying antipsychotic agents : need for new terminology. CNS Drugs 2008; 22: 1047-59 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/18998742].
  • (24) Balon C. Name for New Class of Antipsychotic Medications. Am J Psychiatry 2004; 161:930-931 [Accesible en: http://ajp.psychiatryonline.org/article. aspx?articleid=176824].
  • (25) Healy D. The antidepressant era. Harvard: Harvard University Press, 1997
  • (26) Arbesú Prieto JA, Gonçalves Estella F, Madueño Caro AJ, Pérez Solà V, Villalta Macia L. Guía de buena práctica clínica en algoritmos de decisión en depresión. Madrid: IMC, 2011
  • (27) Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-7 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/20492850].
  • (28) Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 118-24 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/20570110].
  • (29) Bortolato M, Frau R, Orrù M, Bourov Y, Marrosu F, Mereu G, et al. Antipsychotic-like properties of 5-alpha-reductase inhibitors. Neuropsychopharmacology 2008; 33: 3146-56 [Accesible en: http:// www.nature.com/npp/journal/v33/n13/full/ npp200839a.html].
  • (30) Buie LW, Oertel MD, Cala SO. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. Ann Pharmacother. 2006; 40:2200- 4 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/17119103].
  • (31) Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010; 67: 1442-8 [Accesible en: http://archneur.jamanetwork. com/article.aspx?articleid=801762].
  • (32) Kato TA, Watabe M, Tsuboi S, Ishikawa K, Hashiya K, Monji A, et al. Minocycline modulates human social decision-making: possible impact of microglia on personality-oriented social behaviors.PLoS One 2012; 7(7):e40461 [Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0040461].
  • (33) Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-49 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/19895780].
  • (34) Bou Khalil R. Is there any place for macrolides in mood disorders? Med Hypotheses 2012; 78: 86-7 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/22030071].
  • (35) Lu RB, Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, et al. Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works. Med Hypotheses 2012; 79: 280-3 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/22677298].
  • (36) Lee JG, Lee SW, Lee BJ, Park SW, Kim GM, Kim YH. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012; 9: 166-73 [Accesible en: http://psychiatryinvestigation.org/html/abstract. asp?year=2012&vol=9&page=166].
  • (37) Muhonen LH, Lahti J, Sinclair D, Lönnqvist J, Alho H. Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 2008; 3: 20 [Accesible en: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC2569922/].
  • (38) Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsivedisorder. J Clin Psychopharmacol 2010; 30: 34-9 [Abstract en: http://www.ncbi.nlm.nih. gov/pubmed/20075645].
  • (39) Obregon DF, Velasco RM, Wuerz TP, Catalano MC, Catalano G, Kahn D. Memantine and catatonia: a case report and literature review. J Psychiatr Pract 2011; 17: 292-9 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/21775832].
  • (40) Dean O, Giorlando F, Berk M. Nacetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36:78-86 [Accesible en: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3044191/].
  • (41) Ferreira Seiva FR, Amauchi JF, Ribeiro Rocha KK, et al. Effects of N-acetylcysteine on alcohol abstinence and alcohol-induced adverse effects in rats. Alcohol. 2009;43:127–135 [Abstract en: http://www. ncbi.nlm.nih.gov/pubmed/19251114].
  • (42) Gray KM, Carpenter MJ, Baker NL, Desantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169: 805-12 [Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/19251114].
  • (43) LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15:105–110. [Accesible en: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1513138/].
  • (44) Zhou W, Kalivas PW. N-acetyl- cysteine reduces extinction responding and induces enduring reductions in cueand heroin-induced drug-seeking. Biol Psychiatry 2008; 63: 338–340 [Accesible en: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2709691/].
  • (45) Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009;65:841–845. [Accesible en: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2756612/].
  • (46) Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62:652–657 [Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/17445781].
  • (47) Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail biting.CNS Spectrums. 2009;14:357–360 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/17445781].
  • (48) Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a doubleblind, placebo-controlled study. Arch Gen Psychiatry. 2009;66:756–763 [Accesible en: http://archpsyc.jamanetwork.com/article. aspx?articleid=483113].
  • (49) Odlaug BL, Grant JE. N-Acetyl Cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007; 27:227– 229 [Abstract en: http://www.ncbi.nlm.nih. gov/pubmed/17414258
  • (50) Lafleur DL, Pittenger C, Kelmen- di B, Gardner T, Wasylink S, Malison RT, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractoryobsessivecompulsive disorder. Psychopharmacology (Berl) 2006; 184: 254-6 [Abstract en: http:// www.ncbi.nlm.nih.gov/pubmed/16374600].
  • (51) Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacol 2008; 33: 2187–2199 [Accesible en: http://www.nature.com/npp/journal/v33/n9/full/1301624a. html].
  • (52) Asevedo E, Cunha GR, Zugman A, Mansur RB, Brietzke E. N-acetylcysteine as a potentially useful medication to prevent conversion toschizophrenia in at-risk individuals. Rev Neurosci 2012; 23: 353-62 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/22944654].
  • (53) Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomised placebo controlled trial. BMC Med 2012; 10(1):91 [Accesible en: http://www.biomedcentral.com/1741-7015/10/91/abstract ].
  • (54) Boletín Oficial del Estado, 17 de agosto de 2012. Resolución de 2 de agosto de 2012, de la Dirección General de Carte- ra Básica de Servicios del Sistema Nacional de Salud y Farmacia, por la que se procede a la actualización de la lista de medicamentos que quedan excluidos de la prestación farmacéutica en el Sistema Nacional de Salud [Accesible en: http://www.boe.es/boe/ dias/2012/08/17/pdfs/BOE-A-2012-10952. pdf].
  • (55) Chung E, Prelli F, Dealler S, Lee WS, Chang YT, Wisniewski T. Styryl-based and tricyclic compounds as potential antiprion agents. PLoS One 2011;6(9):e24844 [Accesible en: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3172287/].
  • (56) Sasvari Z, Bach S, Blondel M,Nagy PD. Inhibition of RNA recruitment and replication of an RNA virus by acri- dine derivatives with known anti-prion activities. PLoS One 2009; 4(10):e7376[Accesible en: http://www.plosone.org/ar- ticle/info%3Adoi%2F10.1371%2Fjournal.pone.0007376].
  • (57) van Soolingen D, Hernandez-Pan- do R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5(9). pii: e12640 [Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0012640].
  • (58) Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents . 2012; 39: 376-80 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/22445204].
  • (59) Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 2012; 56: 3758-66 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/22508310].
  • (60) Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149: 1284-97 [Abstract]
  • (61) Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the preven- tion and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012; 23: 200-5 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/21427067].
  • (62) Petrascheck M, Ye X, Buck LB.An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature 2007;450: 553-6 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/18033297].
  • (63) Zarse K, Ristow M. Anti- depressants of the serotonin-antagonist type increase body fat and decrease lifespan of adult Caenorhabditis elegans. PLoS One 2008; 3(12):e4062 [Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0004062].
Fuente de los datos: Dialnet